GSK Begins Detailing Xenical Ahead Of OTC Switch Opportunity
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline's Consumer Healthcare division will detail the weight-loss therapy, focusing on diabetes risk reduction data recently added to labeling. Xenical was last detailed by Roche in November 2003. The Rx-to-OTC application is planned for mid-year.You may also be interested in...
Sosei Considers Future Of Fibromyalgia Candidate AD 337 After Failed Phase II Trial
Sosei Considers Future Of Fibromyalgia Candidate AD 337 After Failed Phase II Trial
Sosei Considers Future Of Fibromyalgia Candidate AD 337 After Failed Phase II Trial
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: